Bank of Montreal’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $472K | Buy |
8,658
+295
| +4% | +$15.5K | ﹤0.01% | 2493 |
|
|
2026
Q1 | $398K | Sell |
8,363
-2,105
| -20% | -$111K | ﹤0.01% | 2501 |
|
|
2025
Q4 | $549K | Sell |
10,468
-176,751
| -94% | -$10.6M | ﹤0.01% | 2267 |
|
|
2025
Q3 | $12.1M | Sell |
187,219
-306,524
| -62% | -$17.6M | ﹤0.01% | 969 |
|
|
2025
Q2 | $24M | Buy |
+493,743
| New | +$19.1M | 0.01% | 675 |
|
|
2024
Q4 | – | Sell |
-5,620
| Closed | -$266K | – | 3579 |
|
|
2024
Q3 | $266K | Sell |
5,620
-1,936
| -26% | -$98.2K | ﹤0.01% | 2858 |
|
|
2024
Q2 | $473K | Buy |
7,556
+1,574
| +26% | +$91K | ﹤0.01% | 2444 |
|
|
2024
Q1 | $434K | Buy |
5,982
+2,582
| +76% | +$185K | ﹤0.01% | 2536 |
|
|
2023
Q4 | $233K | Sell |
3,400
-1,837
| -35% | -$102K | ﹤0.01% | 3025 |
|
|
2023
Q3 | $267K | Sell |
5,237
-198
| -4% | -$10.2K | ﹤0.01% | 2894 |
|
|
2023
Q2 | $322K | Buy |
+5,435
| New | +$308K | ﹤0.01% | 2892 |
|
|
2022
Q4 | – | Sell |
-3,904
| Closed | -$265 | – | 4026 |
|
|
2022
Q3 | $265 | Sell |
3,904
-309
| -7% | -$22.4K | ﹤0.01% | 3017 |
|
|
2022
Q2 | $313 | Sell |
4,213
-115,742
| -96% | -$6.8M | ﹤0.01% | 2988 |
|
|
2022
Q1 | $7.75M | Buy |
119,955
+115,003
| +2,322% | +$7.22M | ﹤0.01% | 1260 |
|
|
2021
Q4 | $397K | Buy |
4,952
+1,256
| +34% | +$110K | ﹤0.01% | 2560 |
|
|
2021
Q3 | $416K | Buy |
3,696
+1,042
| +39% | +$131K | ﹤0.01% | 2965 |
|
|
2021
Q2 | $387K | Buy |
2,654
+1,232
| +87% | +$150K | ﹤0.01% | 2962 |
|
|
2021
Q1 | $171K | Sell |
1,422
-816
| -36% | -$123K | ﹤0.01% | 3182 |
|
|
2020
Q4 | $423K | Buy |
2,238
+2,190
| +4,563% | +$259K | ﹤0.01% | 2801 |
|
|
2020
Q3 | $4K | Sell |
48
-909
| -95% | -$80.6K | ﹤0.01% | 4491 |
|
|
2020
Q2 | $90K | Sell |
957
-1,407
| -60% | -$82.3K | ﹤0.01% | 3140 |
|
|
2020
Q1 | $93K | Sell |
2,364
-45,150
| -95% | -$2.33M | ﹤0.01% | 2623 |
|
|
2019
Q4 | $2.89M | Sell |
47,514
-32,566
| -41% | -$1.78M | ﹤0.01% | 1675 |
|
|
2019
Q3 | $3.28M | Sell |
80,080
-29,680
| -27% | -$1.42M | ﹤0.01% | 1387 |
|
|
2019
Q2 | $5.17M | Buy |
109,760
+13,750
| +14% | +$550K | ﹤0.01% | 1187 |
|
|
2019
Q1 | $3.43M | Buy |
96,010
+1,690
| +2% | +$58.4K | ﹤0.01% | 1371 |
|
|
2018
Q4 | $2.69M | Sell |
94,320
-5,613
| -6% | -$195K | ﹤0.01% | 1372 |
|
|
2018
Q3 | $4.43M | Buy |
99,933
+7,350
| +8% | +$385K | ﹤0.01% | 1260 |
|
|
2018
Q2 | $5.44M | Buy |
92,583
+47,850
| +107% | +$2.73M | ﹤0.01% | 1127 |
|
|
2018
Q1 | $2.04M | Buy |
44,733
+42,795
| +2,208% | +$1.77M | ﹤0.01% | 1555 |
|
|
2017
Q4 | $45K | Hold |
1,938
| – | – | ﹤0.01% | 3297 |
|
|
2017
Q3 | $34K | Buy |
1,938
+300
| +18% | +$5.44K | ﹤0.01% | 3366 |
|
|
2017
Q2 | $26K | Hold |
1,638
| – | – | ﹤0.01% | 3437 |
|
|
2017
Q1 | $36K | Buy |
+1,638
| New | +$32.2K | ﹤0.01% | 3185 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Bank of Montreal's CRSP Position: Q2 2026 in Review
Bank of Montreal increased its CRISPR Therapeutics (CRSP) stake by 3.5% in Q2 2026, buying an estimated $15.5K and bringing the position to 8,658 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #2493.
Bank of Montreal first reported a position in CRSP in Q1 2017 and has held it in 34 quarters since. The position peaked at $24M in Q2 2025. 490 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Bank of Montreal held 8,658 shares of CRISPR Therapeutics worth $472K as of Q2 2026.
- Bank of Montreal bought 295 CRISPR Therapeutics shares in Q2 2026, an estimated $15.5K.
- CRISPR Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2493 holding.
- Bank of Montreal first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 34 quarters since.
- Bank of Montreal's CRISPR Therapeutics position peaked at $24M in Q2 2025.
- 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.